Studies proposed here concern a novel phospholipase C-epsilon (PLC?) that we propose mediates beneficial blood glucose-lowering actions of the glucagon-like peptide-1 receptor (GLP-1R) agonist Byetta in patients with type 2 diabetes mellitus (T2DM). The central hypothesis we present is that there exists coupling of the pancreatic beta-cell GLP-1R to cAMP production with consequent activation of PLC? in order to potentiate glucose-stimulated insulin secretion (GSIS) from the islets of Langerhans. By understanding the nature of this unconventional cAMP signaling mechanism, we hope to further drug discovery efforts that seek to identify GLP-1R agonists that are pure insulin secretagogues and that do not induce dangerous side effects such as pancreatitis and cancer.
Aim 1 : Byetta might restore insulin secretion in T2DM by facilitating a "late step" of exocytosis that is under te control of PLC?. Using human islets or islets of PLC? KO mice, this hypothesis will be tested in perfusion or static incubation assays of GSIS. A first goal is to determine if PLC? mediates the action of Byetta to potentiate 1st and/or 2nd phase GSIS, or to potentiate "triggering" and "amplification" mechanisms of GSIS. Next, single cell patch clamp assays in combination with 2-photon confocal microscopy of secretory granule dynamics will be performed to test if PLC? activation explains diacylglycerol (DAG) and protein kinase C (PKC) mediated actions of Byetta to facilitate exocytosis. To evaluate the in vivo action of Byetta, glucoregulation will be studied using Pdx-1-hGLP1R:Glpr-/- mice in which there is a beta-cell specific KO of PLC?. Since Pdx-1-hGLP1R:Glpr-/- mice express the GLP-1R only in the pancreas, specific activation of the beta-cell GLP-1R by administered Byetta will be possible. We predict that a beta-cell specific KO of PLC? will disrupt the action of Byetta to potentiate GSIS in vivo.
Aim 2 : Byetta might also restore insulin secretion in patients with T2DM by sensitizing beta cells to the stimulatory effect of glucose metabolism. More specifically, we propose that Byetta acts via Epac2, Rap1, and PLC? to restore glucose metabolism-dependent closure of K-ATP channels in beta cells of T2DM patients. Our hypothesis embraces a new model of stimulus-secretion coupling in which the sulfonylurea receptor-1 (SUR1) subunit of K-ATP channels acts as a molecular scaffold to allow the formation of a signal transduction complex comprised of Epac2, Rap1, and PLC?. Importantly, we demonstrate that cAMP sensor Epac2 binds to SUR1, and that this interaction is facilitated by H-Ras GTPase acting at a Ras-association (RA) domain of Epac2. Thus, we hypothesize that Byetta acts in concert with growth factors or possibly secreted insulin to activate PLC?, to stimulate PIP2 hydrolysis, and to modulate the ATP and Mg-ADP sensitivity of K-ATP channels in order to close the channels. This hypothesis concerning a novel mechanism of ion channel modulation will be tested in assays of K-ATP channel activity using human islets or islets of Epac2 and PLC? knockout (KO) mice. Summary: The long-term goal of this project concerns our interest in determining the molecular basis for beneficial blood glucose-lowering properties of GLP-1R agonists in patients with T2DM.
A new strategy for the treatment of type 2 diabetes mellitus (T2DM) involves the administration of a metabolically stable GLP-1 mimetic (Byetta) or a GLP-1 analog (Victoza), each of which stimulates insulin secretion by activating a pancreatic beta-cell GLP-1 receptor positively linked to the production of cAMP. The main goal of the studies outlined here is to identify the beta-cell cAMP signal transduction pathway that mediates the rapid action of GLP-1 receptor agonists to restore the missing first phase kinetic component of glucose-stimulated insulin secretion in patients diagnosed with T2DM. The significance of such studies is that they have the potential to dramatically enhance our understanding of how GLP-1-based pharmaceuticals exert beneficial antidiabetogenic actions to stimulate insulin secretion, and to lower levels of blood glucose, in patients diagnosed with T2DM.
|Holz, George G; Leech, Colin A; Chepurny, Oleg G (2014) New insights concerning the molecular basis for defective glucoregulation in soluble adenylyl cyclase knockout mice. Biochim Biophys Acta 1842:2593-600|
|Nadkarni, Prashant; Chepurny, Oleg G; Holz, George G (2014) Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci 121:23-65|
|Holz, George G; Chepurny, Oleg G; Leech, Colin A (2013) Epac2A makes a new impact in *-cell biology. Diabetes 62:2665-6|
|Clardy-James, Susan; Chepurny, Oleg G; Leech, Colin A et al. (2013) Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagon-like peptide-1. ChemMedChem 8:582-6|
|Chepurny, Oleg G; Bertinetti, Daniela; Diskar, Mandy et al. (2013) Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag. Mol Endocrinol 27:1267-82|
|Chen, Haijun; Tsalkova, Tamara; Chepurny, Oleg G et al. (2013) Identification and characterization of small molecules as potent and specific EPAC2 antagonists. J Med Chem 56:952-62|
|Smrcka, Alan V; Brown, Joan Heller; Holz, George G (2012) Role of phospholipase Cýý in physiological phosphoinositide signaling networks. Cell Signal 24:1333-43|
|Leech, Colin A; Dzhura, Igor; Chepurny, Oleg G et al. (2011) Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic ? cells. Prog Biophys Mol Biol 107:236-47|
|Dzhura, Igor; Chepurny, Oleg G; Leech, Colin A et al. (2011) Phospholipase C-ýý links Epac2 activation to the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans. Islets 3:121-8|
|Leech, Colin A; Dzhura, Igor; Chepurny, Oleg G et al. (2010) Facilitation of ß-cell K(ATP) channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac. Islets 2:72-81|
Showing the most recent 10 out of 20 publications